What's hot
View all perspectives
David Liew drdavidliew
1 year 3 months ago
I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst @RheumNow https://t.co/Q8dIHiIYQk
Mrinalini Dey DrMiniDey
1 year 3 months ago
#EULARBest
OP0156- validation & prevalence of D2T RA
Data from @BrighamResearch BRASS
In this cohort, the #EULAR definition of D2TRA correctly identified a subset of RA pts who have not achieved low disease activity despite multiple b/ts DMARD treatments
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey
1 year 3 months ago
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs
>1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs
@RheumNow #EULAR2024
Dr. John Cush RheumNow
1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.
Dr. Antoni Chan synovialjoints
1 year 3 months ago
Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8
Dr. Antoni Chan synovialjoints
1 year 3 months ago
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
David Liew drdavidliew
1 year 3 months ago
Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively?
VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed.
I’ll admit, I’m still not game!
#EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov
David Liew drdavidliew
1 year 3 months ago
How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis?
Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed.
#EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC
Mrinalini Dey DrMiniDey
1 year 3 months ago
OP0131 on occurrence & predictors of #DMARD treatment failure in #RA
8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure
In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs
Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey
1 year 3 months ago
🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA
📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA
💊MTX after start of advanced therapy protective of D2T RA
@RheumNow #EULAR2024
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzumab led to profound circulatory depletion in #lupus nephritis & those w sustained depletion had better complete renal response than those who didn’t @RheumNow https://t.co/2KTZBR2njk
Dr. Antoni Chan synovialjoints
1 year 3 months ago
GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ
Dr. Antoni Chan synovialjoints
1 year 3 months ago
Poster tours at #EULAR2024.
A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
Poster Hall